| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:37 UTC |
|---|
| HMDB ID | HMDB0014434 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Atomoxetine |
|---|
| Description | Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia ] |
|---|
| Structure | CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1 InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Tomoxetine | ChEBI | | Tomoxetina | ChEBI | | Tomoxetine | ChEBI | | Tomoxetinum | ChEBI | | Tomoxetine hydrochloride, (-)-isomer | HMDB | | HCL, Atomoxetine | HMDB | | Hydrochloride, atomoxetine | HMDB | | Strattera | HMDB | | Atomoxetine hydrochloride | HMDB | | Tomoxetine hydrochloride, (+-)-isomer | HMDB | | Atomoxetine HCL | HMDB | | N-Methyl-gamma-(2-methylphenoxy)benzenepropanamine hydrochloride | HMDB | | Tomoxetine hydrochloride, (+)-isomer - T351671 | HMDB |
|
|---|
| Chemical Formula | C17H21NO |
|---|
| Average Molecular Weight | 255.3547 |
|---|
| Monoisotopic Molecular Weight | 255.162314299 |
|---|
| IUPAC Name | methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine |
|---|
| Traditional Name | atomoxetine |
|---|
| CAS Registry Number | 82248-59-7 |
|---|
| SMILES | CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1 |
|---|
| InChI Identifier | InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1 |
|---|
| InChI Key | VHGCDTVCOLNTBX-QGZVFWFLSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Phenol ethers |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Phenol ethers |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenoxy compound
- Phenol ether
- Alkyl aryl ether
- Toluene
- Aralkylamine
- Monocyclic benzene moiety
- Secondary aliphatic amine
- Ether
- Secondary amine
- Organooxygen compound
- Organonitrogen compound
- Amine
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.0039 g/L | Not Available | | LogP | 3.9 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 164.2 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.65 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 13.3074 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.38 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 30.6 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1761.4 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 342.7 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 184.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 199.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 170.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 492.5 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 478.5 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 139.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1265.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 467.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1342.9 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 324.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 347.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 302.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 173.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 7.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Atomoxetine,1TMS,isomer #1 | CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C)C1=CC=CC=C1 | 2205.6 | Semi standard non polar | 33892256 | | Atomoxetine,1TMS,isomer #1 | CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C)C1=CC=CC=C1 | 2189.1 | Standard non polar | 33892256 | | Atomoxetine,1TMS,isomer #1 | CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C)C1=CC=CC=C1 | 2692.7 | Standard polar | 33892256 | | Atomoxetine,1TBDMS,isomer #1 | CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 | 2456.7 | Semi standard non polar | 33892256 | | Atomoxetine,1TBDMS,isomer #1 | CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 | 2372.8 | Standard non polar | 33892256 | | Atomoxetine,1TBDMS,isomer #1 | CC1=CC=CC=C1O[C@H](CCN(C)[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 | 2797.6 | Standard polar | 33892256 |
|
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Atomoxetine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0007-9510000000-b436c1286414de57d10e | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Atomoxetine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-qTof , Positive-QTOF | splash10-0a4i-0690000000-494128ae0f3b90b415b3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0002-0900000000-456e1257123470a131c2 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0190000000-0f4cf059747adb026b96 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0090000000-ecaeebd63dc195659e57 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0002-0900000000-6da1a9a3edfed770c2cd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-00xs-0900000000-d71f5b857319380ce595 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-01bc-2900000000-37eb3191934e545cc338 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-014l-6900000000-6be893f7d4702639eac2 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0190000000-c2030f3f981d83eacf57 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0a4i-0190000000-3c27da7fa8c958a76be1 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0002-0900000000-133c9cb2f2383aa0fe8a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-00r5-1900000000-b68a2013855cb02e4512 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-01bd-1900000000-c4fd6863785e44cc724e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-014l-3900000000-4529fcb6c89f3acafac9 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine LC-ESI-ITFT , positive-QTOF | splash10-0002-0900000000-06348bdc8d24fed52e75 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine , positive-QTOF | splash10-0a4i-0690000000-494128ae0f3b90b415b3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine 45V, Positive-QTOF | splash10-0002-0900000000-133c9cb2f2383aa0fe8a | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine 30V, Positive-QTOF | splash10-0a4i-0190000000-3c27da7fa8c958a76be1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Atomoxetine 45V, Positive-QTOF | splash10-0002-0900000000-6da1a9a3edfed770c2cd | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atomoxetine 10V, Positive-QTOF | splash10-0a6r-0090000000-baa3d0729ad3bb59a89f | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atomoxetine 20V, Positive-QTOF | splash10-054p-7690000000-47a6bba7ee3a8fb547e3 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atomoxetine 40V, Positive-QTOF | splash10-0006-9400000000-2bb86246ec7cd0612674 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atomoxetine 10V, Negative-QTOF | splash10-0udi-0090000000-02a8368dee3cab1e1702 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atomoxetine 20V, Negative-QTOF | splash10-0udi-2290000000-6d5c426420a70e542e1c | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Atomoxetine 40V, Negative-QTOF | splash10-0a6r-9710000000-6adb2c5abb0cab9b62a8 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | |
|---|
| Biospecimen Locations | |
|---|
| Tissue Locations | Not Available |
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00289 | | details | | Urine | Expected but not Quantified | Not Quantified | Not Available | Not Available | Taking drug identified by DrugBank entry DB00289 | | details |
|
|---|
| Abnormal Concentrations |
|---|
| Not Available |
|---|
| Predicted Concentrations |
|---|
| |
| Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | None |
|---|
| Associated OMIM IDs | None |
|---|
| External Links |
|---|
| DrugBank ID | DB00289 |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | Not Available |
|---|
| KNApSAcK ID | Not Available |
|---|
| Chemspider ID | 49516 |
|---|
| KEGG Compound ID | Not Available |
|---|
| BioCyc ID | Not Available |
|---|
| BiGG ID | Not Available |
|---|
| Wikipedia Link | Atomoxetine |
|---|
| METLIN ID | Not Available |
|---|
| PubChem Compound | 54841 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 127342 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | Not Available |
|---|
| MarkerDB ID | Not Available |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Not Available |
|---|
| Material Safety Data Sheet (MSDS) | Not Available |
|---|
| General References | - Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
- Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
- Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. [PubMed:16113620 ]
- Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. [PubMed:16259536 ]
- Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. [PubMed:16555170 ]
- Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. [PubMed:16649828 ]
- McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. [PubMed:17388708 ]
- Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. [PubMed:19785510 ]
|
|---|